
| Disease Domain | Count |
|---|---|
| Nervous System Diseases | 2 |
| Endocrinology and Metabolic Disease | 2 |
| Infectious Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 10 |
Target |
Mechanism L-type calcium channel blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date12 Dec 2025 |
Target |
Mechanism mAChRs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date31 Jul 2025 |
Target |
Mechanism nAChRα4&β2 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 May 2006 |
Start Date11 May 2026 |
Sponsor / Collaborator |
Start Date04 Mar 2026 |
Sponsor / Collaborator |
Start Date06 Feb 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Varenicline Tartrate ( nAChRα4&β2 ) | Xerophthalmia More | Approved |
Etripamil ( L-type calcium channel ) | Paroxysmal supraventricular tachycardia More | NDA/BLA |
Aceclidine ( mAChRs ) | Presbyopia More | NDA/BLA |
OC-02 ( nAChRs ) | Dry Eye Syndromes More | Phase 3 |
Aceclidine/Brimonidine ( ADRA2 x mAChRs ) | Presbyopia More | Phase 3 |





